Figure 2.
Antitumor activity of Taxotere, Trastuzumab, and Cetuximab in DU145 and PC-3 xenografted models. (a) Representative IHC image of FFPE DU145 and PC-3 xenografts probed with an anti-HER2, anti-EGFR or anti-pSTAT3 antibody. Scale bar: 50 µm. (b) Male SCID mice bearing established (100mm3) DU145 or PC-3 xenograft models were treated with Trastuzumab (10mg/Kg) i.p., Cetuximab (1mg/mouse) i.p., Taxotere (6.66mg/Kg) i.v., given alone, in dual or triple combination; control mice were treated with saline. Treatments were administered weekly for 5 consecutive weeks (arrow). Mean tumor volumes ± SD are shown (n = 4–5). (c) DU145 and PC-3 tumor volumes 1 week after the end of treatments (at day 57 and day 50, respectively). ** p < .01, ***p < .001 by unpaired t-test.